Editor’s be aware: This text was written by my buddy and colleague, Gary Kaminsky. Gary is representing Corey A. Burchman, MD, within the DEA listening to on the discover of proposed rulemaking to switch marijuana from schedule I to schedule III of the Managed Substances Act. Dr. Burchman is a longtime revered hashish advocate. On this article, Gary supplies an informative and entertaining account of the hearings and Dr. Burchman’s testimony. – Rod Kight
MUSINGS FROM THE DEA SCHEDULE III HEARING
I had the distinctive alternative to take part on this week’s listening to in Arlington to find out whether or not marihuana has a At the moment Accepted Medical Use (“CAMU”) mandating its removing from Schedule I of the Managed Substance Act of 1970 (“CSA”). From knowledgeable standpoint, I used to be honored to have the ability to assist put together my shopper, Dr. Corey A Burchman to testify in assist. On a private stage, I felt like I used to be on the World Cup finals watching my buddy “Leo Messi” rating a hat trick.
It was an invigorating expertise witnessing the DEA aggressively argue in favor of the CAMUs that our beloved plant has and successfully crush the “refer insanity” opposition to marihuana’s many efficacious therapeutic advantages. The gravitas of this listening to should to be decided however the truth that the DOJ is advocating to facilitate the broader use of marihuana within the US is, in itself, groundbreaking.
The opposite outstanding commentary I had was that we had been witnessing two sides arguing completely different instances.
The DEA’s argument was easy – marihuana has not less than one CAMU. As James J. Schwartz, the DEA’s senior lawyer clearly acknowledged in his opening assertion, this matter is about whether or not marihuana has one CAMU, not about legalization. The opposition then again appeared to need to low cost the recognized and confirmed science and give attention to the FDA/DEA/HHS course of and the state system for dispensation. I liken it to 2 ships passing within the night time.
One would suppose proving one CAMU could be a straightforward activity, since this plant has been used for 1000’s of years, largely for therapeutic causes and 40 states have permitted its use medically. Nonetheless, marihuana has been the sufferer of politicized laws for the previous century, most pointedly Nixon’s hate of the hippies resulting in the enactment of the CSA inserting marihuana on the identical schedule as heroin, LSD and MNDA.
The following 50 plus years have seen marihuana regulation evolve on this very fragile base right into a confused and inconsistent sequence of legislative and regulatory dictates coupled with a promulgation of state-by-state acceptance and the accompanying disparate regulatory schemes.
It’s clear for the April DOJ Govt Order that this listening to was in regards to the CAMU of “marihuana.” Not about “medical marihuana” not about “leisure marihuana” however about whether or not this wonderful plant has not less than one medical use. For these of us who’ve devoted our blood sweat and tears to this business, this might not be revelatory. There is just one plant Hashish Sativa L that’s crammed with over 150 recognized cannabinoids, a quantity for which there’s definitive scientific proof of medical efficacy. For the Legal professional Common to mandate an “expeditious” course of to indicate this and for the DEA to, as aggressively because it has opposed this, advocate for it, is nothing in need of historic.
I can attest that the DEA is taking this very critically and placing forth its greatest effort to hold it burden of proof. Dr. Chiapperino, the Director of the FDA Managed Substance Part and the DEA’s first witness, successfully defined the HHS course of, the evaluation and its conclusion that marihuana had not less than three CAMUs for (1) anorexia, (2) nausea and (3) ache administration. He did this regardless of vociferous cross from counsel for the reefer insanity opposition who appeared extra intent on making an attempt to make a document for his or her pending federal courtroom appeals than truly litigate this administrative listening to. We heard hours of relentless arguments framed as questions from opposing counsel seemingly designed solely to permit counsel to get sure of their views on the document for future use. Sadly, for them, most, if not all factors they might have made had been wholly irrelevant to the gravamen of the listening to. All medicine carry dangers and require care and data in use.
The assault on the HHS course of, whereas offering nice alternative for them to espouse conspiracy theories of presidency misfeasance and grandstand for his or her marihuana hating shoppers, actually has little to do with this listening to. That is about CAMU and whether or not the DEA can show there may be not less than one medical use for marihuana. SAM, some of the vocal opposition events, trumpeted its lawyer’s potential to get the great Physician to testify that HHS used a unique take a look at to approve medical marihuana than it had used beforehand implying that the federal government skewed its complete ten month lengthy deliberative course of involving 1000’s of man hours from professionals in three businesses to get some desired end result.
It’s clear that the rationale the two-factor take a look at was in the end used was marihuana is a singular substance and doesn’t match into the businesses’ earlier drug analyses. For one it’s a plant containing quite a few molecules with substantial potential CAMU and in contrast to different medicine, it’s already prevalently being distributed and used throughout the nation. A spherical peg in a sq. gap as we are saying requiring a unique take a look at to find out the efficacy and accordingly, acceptable schedule. Extra notably, the DOJ Workplace of Authorized Counsel’s (OLC) 2024 opinion discovered that the HHS’s two-part take a look at was ample and in reality mandated or not it’s used.
Dr. Burchman took the stand on the afternoon of day two testifying in clear and articulate phrases the substantial medical worth of marihuana to his ache administration apply on the Dartmouth Geisel Faculty of Medication. Dr. Burchman highlighted the substantial efficacy marihuana confirmed in transitioning sufferers off very dangerous and addictive opioids beforehand the first drug used for continual ache administration. He cited quite a few scientific research supporting this in addition to actual life examples of his expertise along with his tons of of sufferers. Dr. Burchman offered the courtroom with a flowery analogy stating that “withdrawal from opioids is sort of a dumpster hearth,” whereas withdrawal from marihuana is “extra like a dying glowing ember of a campfire.”
Possibly the spotlight of Dr. Burchman’s testimony and the primary couple days of the listening to got here when he defined to the courtroom the human physique’s natural endocannabinoid system with its CB receptors and the way the important thing cannabinoids of THC and CBD connect thereto to supply ache administration therapeutic efficacy. At one level, Dr. Burchman acknowledged that the human physique is crammed with billions of those receptors which in essence means the human physique has marihuana working it by way of it naturally. He additionally offered the a lot wanted clarification of the time period “full spectrum” and the significance of its use in treating sufferers. Listening to these defined in federal courtroom for possibly the primary time was nothing in need of outstanding and clearly made the case for CAMU.
Extremely, opposition counsel appeared fully shocked by Dr. Burchman’s testimony resorting to ridiculous and determined objections to him as a witness on due course of grounds claiming they had been unaware he would testify about particular person affected person experiences. These objections had been overruled by the ALJ and led to him studying into the document the DEA’s assertion of case which particularly acknowledged that Dr. Burchman could be testifying about precisely this matter.
After that, counsel realizing they might not low cost his direct expertise treating sufferers and his experience in ache administration, resorted to making an attempt to discredit Dr. Burchman comically asking him if he was excessive on the listening to and when was the final time he received excessive. Not surprisingly, when his testimony resumed on day three, counsel, as I had predicted, didn’t even take its full allocation of cross examination time, waiving it in concern of eliciting additional assist for the DEA’s case.
We did get one entertaining second although when counsel for SAM violated the cardinal rule of litigation and requested Dr. Burchman a query for which counsel clearly didn’t know the reply. When requested whether or not there had ever been an FDA permitted botanical plant drug, Dr. Burchman, with a smile, replied, “I’m glad you requested that,” and preceded to testify in regards to the current FDA breakthrough remedy designation it granted to VER-01, a First-in-Class Non-Opioid, Hashish-Primarily based Investigational Therapy for Persistent Low Again Ache. VER-01 by the best way, is a full spectrum drug containing 2.5 mg of THC and CBD and CBG.
The DEA’s redirect elicited a fabric level from Dr. Burchman the place he defined the distinction between “trigger” and “correlation.” Dr. Burchman defined that the research that the opposition had been espousing had been merely examples of non-causal correlations which don’t positively present any connection between marihuana and the harms they declare are connected to make use of. In reality. Dr. Burchman was comparatively conversant in nearly each examine they introduced and was in a position to low cost all of them.
Dr. Burchman’s testimony ended with the ALJ requesting the chance to ask a query which offered a closing mike drop to the DEA’s case. He requested what definition of “medical marijuana” Dr. Burchman was utilizing in his testimony. A lot to the delight of the business, Dr. Burchman testified that there isn’t a medical or leisure marihuana, there may be solely marihuana which is Hashish Sativa L.
With one week within the books, we will solely anticipate the following. I’m assured the DEA carried its burden and don’t see how the opposition will have the ability to refute the clear unequivocal displaying of CAMU. That being stated, we’re in for a combat because the opposition intends to attraction any choice and proceed to perpetuate its reefer insanity dogma. As all of us get pleasure from our nation’s 250th anniversary, we will relaxation straightforward that marihuana is lastly positioned to doubtlessly take the following step. Keep in mind it was marihuana that financed the revolution as the first money crop of our founders.
July 3, 2026
Gary Kaminsky has over 39 years of expertise as a regulatory compliance lawyer, the previous decade within the Hashish (Hemp and Marihuana) business. Gary’s experience is in advising, growing and implementing regulatory enterprise threat administration infrastructure designed to mitigate lapses that may trigger disruption to companies.
Gary has labored at and suggested plenty of US multi-state operators and different corporations throughout the availability chain within the Hashish business. Because the passage of the 2018 Farm Invoice, Gary has been actively concerned within the improvement of “greatest practices” for corporations working within the rising hemp-derived infused beverage business, advising provide chain members on regulatory points associated to, amongst different issues, labelling, distribution and advertising and marketing of merchandise.
Gary is continuously turned to as an informational useful resource by state and federal regulators and legislation enforcement in addition to an writer and panelist on Hashish business points.
Gary’s distinguished profession started as a senior lawyer with the Enforcement Division of the U.S. SEC in Washington in 1986. He’s a co-founder, COO, CCO and Common Counsel for 2 various funding fund corporations and CCO and Counsel for Susquehanna Funding Group, a number one proprietary buying and selling agency, preceded by a place as a securities and regulatory lawyer with Dechert, LLP.
He obtained a BA from the College of North Carolina at Chapel Hill, and his Juris Physician from the State College of New York at Buffalo.
